Absci shares surge 10.49% intraday as AI-designed antibody ABS-201 enters clinical evaluation for androgenetic alopecia.
ByAinvest
Thursday, Dec 4, 2025 10:51 am ET1min read
ABSI--
Absci surged 10.49% intraday trading, as the company announced its AI-designed antibody ABS-201 has begun clinical evaluation in a Phase 1/2a trial for androgenetic alopecia. On December 4, 2025, the first healthy volunteers received the drug, marking the start of the clinical assessment phase. Absci is a clinical-stage biopharmaceutical company leveraging generative AI to develop breakthrough antibody therapies targeting challenging targets such as the PRLR receptor.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet